US approves 1st drug developed to prevent chronic migraines - InfoNews

Current Conditions

Sunny
12.2°C

US approves 1st drug developed to prevent chronic migraines

This May 10, 2018, image provided by Amgen Inc. shows an artist's rendering of the packaging for the drug Aimovig, the first in a new class of long-acting drugs designed to prevent chronic migraines. On Thursday, May 17, 2018, the Food and Drug Administration approved the medication, clearing the monthly shot for sale. (Amgen Inc. via AP)
May 17, 2018 - 4:24 PM

TRENTON, N.J. - U.S. regulators Thursday approved the first drug designed to prevent chronic migraines.

The Food and Drug Administration's action clears the monthly shot Aimovig (AIM'-oh-vig) for sale. It's the first in a new class of long-acting drugs for preventing migraines. Three other shots are expected to win approval by next year, and several pills for preventing migraines are being tested.

Current prevention treatments include pills originally developed for epilepsy and other conditions and the wrinkle reducer Botox, but many patients abandon them because they don't help much or cause serious side effects.

Amgen Inc. of Thousand Oaks, California, and Swiss drug giant Novartis AG developed Aimovig. Injected monthly just under the skin using a penlike device, the drug will cost $6,900 per year without insurance.

Migraines can cause disabling symptoms: throbbing headaches, nausea and vomiting, and sensitivity to light and sound. About 10 million Americans get them frequently. They're most common in people in their 30s, mostly women, and can last for several hours or even days.

In one study, patients given Aimovig saw their migraine days cut from eight to four a month, on average. Those who got dummy shots had a reduction of two. Each patient group had similar minor side effects, mostly colds and respiratory infections.

Some patients saw their migraines completely eliminated, said Sean Harper, Amgen's research director.

Aimovig and the migraine drugs in development target a substance called CGRP whose levels spike in the blood during a migraine, triggering symptoms.

The long-term safety of Aimovig, also known as erenumab, hasn't been tested, and Amgen plans to track outcomes in women who become pregnant while taking it.

___

Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma

News from © The Associated Press, 2018
The Associated Press

  • Popular kamloops News
  • Comments
  • Police make arrests in Vernon homicide
    VERNON – RCMP have two people in custody in connection with a suspicious Vernon death now deemed a homicide. Vernon RCMP media relations officer Const. Kelly Brett says in a media rele
  • Kamloops man nabbed in warehouse break-in
    KAMLOOPS - Police have arrested a 43-year-old local man after he broke into a City of Kamloops warehouse, states an RCMP media release. Police say the dog unit was called in after a 6 a.m. t
  • How Kamloops got to be the only B.C. city operating a government cannabis store on Oct. 17
    KAMLOOPS - Kamloops is expected to be the only city in the province to have a legal store where you can buy cannabis Wednesday, and it’s all down to being prepared and a chance encounter.
  • TRENDING NOW: Toy mocks dog look-alike
    %%nodefaultimage%% This adorable dog is getting mocked by a robotic toy that looks and sounds like him or her. If you have dogs in the room, they may react to this.
  • Immigrants face hurdles to prove abuse by US agents
    HOUSTON - Within hours of being booked at a Border Patrol station in far West Texas, two teenage sisters from Guatemala came forward to allege that an agent conducted an improper strip search.
View Site in: Desktop | Mobile